Substack · BioEquity Watch
Outpatient Disruptor or Micro-Cap Gamble? : The Asymmetric Case for Immix Biopharma ($IMMX)
Rating: BULLISH | Target Price: $21.20 | Current Price: $8.95 | Implied Change: +155.68%
Desde publicación IMMX −5,4 % α −9,0 p. p. vs S&P 500 · USD